Welcome to our dedicated page for LakeShore Co SEC filings (Ticker: LSBWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LSBWF SEC filings page on Stock Titan is intended to provide access to regulatory disclosures associated with LakeShore Biopharma Co., Ltd and its related securities. Although specific filings are not listed in the provided data, the company has stated that it remains a reporting company with the U.S. Securities and Exchange Commission, even after its transition from The Nasdaq Capital Market to the OTC Pink Open Market.
LakeShore Biopharma’s disclosed regulatory actions include its announcement that Nasdaq issued a delisting determination based on non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and ineligibility for a further compliance period under Listing Rule 5810(c)(3)(A)(iv). Following this determination, the company reported that trading of its ordinary shares and warrants on Nasdaq was suspended and that the securities began trading on the OTC Pink Open Market under LSBCF and LSBWF.
In addition, LakeShore Biopharma has announced that it will furnish a current report on Form 6‑K to the SEC regarding its Agreement and Plan of Merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. The company has also stated that it will prepare and mail a proxy statement to shareholders and file a Schedule 13E‑3 transaction statement with the SEC in connection with the going‑private merger. These documents are expected to describe the terms of the merger, the treatment of ordinary shares, and the role of rollover shareholders.
On Stock Titan, SEC filings for LSBWF and related LakeShore Biopharma securities can be paired with AI-powered summaries that explain the structure and implications of documents such as Forms 6‑K, proxy statements, and Schedule 13E‑3. This helps readers understand how listing changes, merger agreements, and other regulatory events affect the company’s capital structure and the status of its OTC‑traded warrants and shares.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.